This technology uses exogenous Rac1 analogs in their active form to prevent acute lung injury and acute respiratory distress syndrome.
Life-threatening tissue injury to critical organs can occur because of host-pathogen interactions involving proinflammatory receptors. In the lungs, prolonged inflammation from infection leads to acute lung injury (ALI), which can result in acute respiratory distress syndrome (ARDS), a condition that is associated with high mortality. So far, no pharmacological treatments are available for ALI, making it difficult to prevent ARDS in pathogenic cases.
¬ This technology is a method for preventing or treating acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) by administering the activated form of Rac1 (V12Rac1). V12Rac1 is an f-actin stabilizing biologic able to block the lung’s proinflammatory receptor. This technology enriches the lung’s epithelial lining with V12Rac1, preventing prolonged inflammation due to infection. This technology can be used to help prevent and treat ALI and ARDS in subjects diagnosed with or at risk of developing these conditions.
Jahar Bhattacharya, MBBS, DPhil
Patent Pending
IR CU23206, CU23227
Licensing Contact: Jerry Kokoshka
